Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
Holding ETON?
Track your performance easily
ETON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.03 - $15.00
Previous CloseN/A
Volume127.06K
Average Volume (3M)215.65K
Market Cap
$380.34M
Enterprise Value$143.37M
Total Cash (Recent Filing)$13.16M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Mar 13, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding26,634,796
10 Day Avg. Volume314,056
30 Day Avg. Volume215,646
Standard Deviation0.19
R-Squared0.15
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.64
Price to Cash Flow (P/CF)31.30
P/FCF Ratio29.20
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue4.17
Enterprise Value/Gross Profit6.81
Enterprise Value/Ebitda-82.35
Forecast
1Y Price Target
$18.67Price Target Upside29.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Eton Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEton reported $10.3M of revenues, beating consensus estimate of $9.7M.
Market PositioningETON's growing portfolio of orphan drug products is driving better-than-expected market penetration, which could get ETON to its targeted $100M annual revenue run-rate.
Revenue GrowthETON is approaching a revenue inflection point driven by Increlex and ET-400, which may result in profitability with ensuing growing positive cash flow.
Bears Say
Clinical ChallengesClinical hurdles may impede the progress of Eton Pharmaceuticals' drug development efforts.
Dilution ConcernsPotential dilution could negatively impact shareholder value and financial performance of Eton Pharmaceuticals.
Legal And Intellectual Property RisksLegal disputes and intellectual property issues could pose significant obstacles to Eton Pharmaceuticals' operations.
---
Ownership Overview
15.28% Insiders
7.26% Mutual Funds
1.19% Other Institutional Investors
72.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ETON FAQ
What was Eton Pharmaceuticals Inc’s price range in the past 12 months?
Eton Pharmaceuticals Inc lowest stock price was $3.03 and its highest was $15.00 in the past 12 months.
What is Eton Pharmaceuticals Inc’s market cap?
Eton Pharmaceuticals Inc’s market cap is $380.34M.
When is Eton Pharmaceuticals Inc’s upcoming earnings report date?
Eton Pharmaceuticals Inc’s upcoming earnings report date is Mar 13, 2025 which is in 54 days.
How were Eton Pharmaceuticals Inc’s earnings last quarter?
Eton Pharmaceuticals Inc released its earnings results on Nov 12, 2024. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.03.
Is Eton Pharmaceuticals Inc overvalued?
According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Undervalued.
Does Eton Pharmaceuticals Inc pay dividends?
Eton Pharmaceuticals Inc does not currently pay dividends.
What is Eton Pharmaceuticals Inc’s EPS estimate?
Eton Pharmaceuticals Inc’s EPS estimate is >-0.01.
How many shares outstanding does Eton Pharmaceuticals Inc have?
Eton Pharmaceuticals Inc has 26,634,796 shares outstanding.
What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?
Eton Pharmaceuticals Inc reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 15.594%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ETON
---
Eton Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (29.56% Upside)
$18.67 (29.56% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $79.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.5%
Last 30 Days ▲ 35.0%
Last 30 Days ▲ 35.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
248.06%
12-Months-Change
Fundamentals
Return on Equity
-33.35%
Trailing 12-Months
Asset Growth
13.69%
Trailing 12-Months
Company Description
Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines. The company was founded in April 2017 and is headquartered in Deer Park, IL.
---
ETON Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, highlighting significant revenue growth, a strategic acquisition, and achieving profitability ahead of schedule. While there were challenges such as increased administrative expenses and higher discontinuation rates for a specific product, they were outweighed by the company's overall achievements and strategic advancements.Read More>---
ETON Stock 12 Month Forecast
Average Price Target
$18.67
▲(29.56% Upside)
Technical Analysis
Aldeyra Therapeutics
―
ANI Pharmaceuticals
―
Aptevo Therapeutics
―
Catalyst Pharma
―
Bausch Health Companies
―
Zymeworks
―
Best Analysts Covering ETON
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+149.04%
assigned a buy rating 11 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +149.04% per trade.
---